News
MyChesCo on MSN33m
Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported second-quarter 2025 results, highlighting progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback